Protocol Ledger

NCT06707883 · Phase II · ACTIVE NOT RECRUITING

A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Interventional Phase II clinical trial protocol NCT06707883 sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-31 Enrollment: 258 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06707883
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)258 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06707883
Protocol FieldVerified Registry Value
NCT IdentifierNCT06707883
Consolidated Lead SponsorShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment258 participants (ACTUAL)
Registered Start Date2024-12-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI